Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Novik on Benefits/Challenges of Implementing Biosimilars

August 21st 2018

Yelena Novik, MD, associate professor, New York University’s Perlmutter Cancer Center, discusses the benefits and challenges of the global implementation of biosimilars.

Expanded Scalp Cooling Approval Offers Patients More Choices

August 20th 2018

An expanded indication for the Paxman Scalp Cooling System to include the prevention of chemotherapy-related alopecia in patients with solid tumors will increase the population eligible for the therapy dramatically and allow for more personalized treatment options.

TAILORx Findings Augur Less-Toxic Treatment for Patients With Breast Cancer

August 20th 2018

Results from the phase III TAILORx study will enable physicians to reduce the toxicity of treatment for many patients with early stage breast cancer.

Neoadjuvant Immunotherapy Emerges as a New Frontier

August 20th 2018

Although checkpoint blocking immunotherapy has significantly improved outcomes for patients with advanced and metastatic disease, researchers believe the modality also may be effective in the neoadjuvant setting.

Dr. Savin on the Challenges of Developing Biosimilar Clinical Trials

August 17th 2018

Michael A. Savin, MD, assistant professor of medicine, School of Medicine, Oregon Health and Science University, discusses the challenges that come with trying to develop a clinical trial for biosimilars.

CDK4/6 Inhibitors, Other Treatment Advances Show Hope for Patients With Breast Cancer

August 16th 2018

Stephanie L. Graff, MD, discusses the current and evolving landscape of breast oncology and what this means for patients.

Dr. Ligibel on Patient Education to Avoid Breast Cancer Recurrence

August 15th 2018

Jennifer Ligibel, MD, senior physician, Susan F. Smith Center for Women's Cancer at the Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses the resources available for patients to educate themselves on avoiding breast cancer recurrence.

Dr. Formenti Discusses Immunology in Breast Cancer Treatment

August 15th 2018

Silvia Chiara Formenti, MD, chairman, Department of Radiation Oncology, Weill Cornell, associate director, Meyer Cancer Center, radiation oncologist-in-chief, NewYork-Presbyterian Hospital, discusses immunology in the breast cancer treatment landscape.

Tripathy Discusses Developments in HR+ Breast Cancer

August 14th 2018

Debu Tripathy, MD, discusses the evolution of treatment of patients with metastatic HR-positive breast cancer.

Hart Recaps Data With Abemaciclib in HR+/HER2- Breast Cancer

August 11th 2018

Abemaciclib (Verzenio) has emerged as a promising agent for patients with hormone receptor-positive, HER2-negative metastatic breast cancer, according to Lowell L. Hart, MD.

Dr. Novik on CDK4/6 Inhibitor Combinations in Breast Cancer

August 10th 2018

Yelena Novik, MD, associate professor, NYU Langone’s Perlmutter Cancer Center, discusses CDK4/6 inhibitor combinations in breast cancer.

Expert Reinforces Importance of Regional Nodal Irradiation in Breast Cancer

August 10th 2018

Wendy A. Woodward, MD, PhD, highlights encouraging advances and ongoing developments with radiotherapy in breast cancer.

Dr. Tolaney on Selecting Patients for CDK4/6 Inhibitors in Breast Cancer

August 9th 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses selecting patients with estrogen receptor (ER)-positive breast cancer for treatment with CDK4/6 inhibitors.

Dr. Kalinsky on Neratinib and Tucatinib in HER2+ Metastatic Breast Cancer

August 8th 2018

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical School, discusses the potential of neratinib (Nerlynx) and tucatinib in HER2-positive metastatic breast cancer.

Expert Shares Insight on Refinements in Breast Cancer Radiotherapy

August 8th 2018

Naamit K. Gerber, MD, discusses recent advances in radiation therapy in the field of breast cancer.

Dr. Borgen Discusses Axillary Node Dissection in Early-Stage Breast Cancer

August 7th 2018

Patrick I. Borgen, MD, chairman of surgery, director of the Breast Cancer Program, Maimonides Medical Center, discusses axillary node dissection in patients with early-stage breast cancer.

Dr. Murthy on Dual HER2 Blockade in HER2+ Breast Cancer

August 6th 2018

Rashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses dual HER2 blockade in HER2-positive breast cancer.

Dana-Farber Researcher Sees Biomarker Potential in ESR1 Mutations

August 3rd 2018

Rinath M. Jeselsohn, MD, discusses the detection and clinical implications of ESR1 mutations.

Yardley Recaps Breast Cancer Data From ASCO 2018

August 2nd 2018

Denise A. Yardley, MD, weighs in on the recent data reported in breast cancer.

Dr. Murthy on Future of Tucatinib in HER2+ Breast Cancer

August 1st 2018

Rashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the future of tucatinib in HER2-positive breast cancer.